ELND 006 (Compound 30) is a metabolically stable gamma-secretase inhibitor designed to selectively inhibit amyloid beta (Abeta) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Abeta levels in vitro and in vivo. Comparisons with other gamma-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Abeta levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimers disease[1].
Molecular Weight:
455.40
Purity:
99.7
CAS Number:
[1333990-84-3]
Formula:
C20H14F5N3O2S
Target:
Amyloid-beta,gamma-secretase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
